On December 5, 2019, Jiangsu Shuo Shi Biological Technology Co., Ltd. (stock code: "688399") was officially listed and became an enterprise landing on the Science and Technology Board in Taizhou and Central Jiangsu. Dr. Zhang Xu, Chairman of Guoqian Medical Technology (Suzhou) Co., Ltd., as the founder of Jiangsu Shuo Shi Biological Technology Co., Ltd., was invited to perform at the Shanghai Stock Exchange Science and Technology Board.
Zhang Xu, Ph.D. in Medical Biochemistry and Molecular Biology, Karolinska Institute, Sweden, and a specially-appointed expert in the National Thousand Talents Program.
From 2002 to 2005, he served as executive officer and technical director of Yaneng Biotechnology (Shenzhen) Co., Ltd. Asia Energy took the lead in the domestic use of low-density biochips as a technical platform for the application and industrialization of thalassemia, human papillomavirus (HPV) and other genetic and infectious diseases, and eventually became the domestic thalassemia and cervical cancer The main supplier of products such as HPV type detection for early screening.
From 2005 to 2009, he served as a scientist of Cap Biotech (Hong Kong) Co., Ltd. For the first time at home and abroad, Cap Bio broke through the problem that alpha and beta thalassemia cannot be detected simultaneously, and successfully detected 18 high-risk HPV virus subtypes on the polymerase chain reaction platform in the same reaction test tube. A series of important clinical testing products, the company has successfully listed on the Shenzhen Stock Exchange GEM.
In 2010, he founded Jiangsu Shuo Shi Biological Technology Co., Ltd. and served as chairman. After 9 years of development, the company has become a domestic clinical female lower genital tract micro-ecological evaluation system product, and for the first time at home and abroad to break the HPV virus subtype detection at the same time can not carry out the problem of virus load analysis of each subtype virus Recognized by many experts in gynecology at home and abroad, it has become a new weapon for early screening of cervical cancer.
In 2017, he began to focus on mid-early equity investment in medical devices and in vitro diagnostic reagents. He co-founded Guoqian Medical Technology (Suzhou) Co., Ltd. and served as chairman of the board with five other experts and core executives from the "Thousand Talents Program".
Guoqian Venture Capital Management (Suzhou) Co., Ltd.
Guoqian Venture Capital was jointly established by six special experts from the National Thousand Talents Program, including Dr. Zhang Xu, who has successful entrepreneurship or industrial experience in various segments of medical devices, and Suzhou Institute of Medical Engineering, Chinese Academy of Sciences and other shareholders. A professional and market-oriented venture capital institution focusing on equity investment in early-stage innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Based on the business philosophy of “achieving the dreams of others”, Guoqian Venture Capital seeks for high-end scientific and technological talents centered on experts from the National Thousand Talents Program in the transformation of scientific and technological achievements, the introduction of technological projects, the evaluation of innovative and entrepreneurial projects, and the landing of innovative and entrepreneurial projects Quality investment target, while providing value-added services. At present, it has invested in Aishi Medical (Ophthalmology AI), Ruiqian Technology (Pathology AI), Xinqing Medical (in vitro artificial heart), Spectrum Life (mass spectrometry detection), Huanuo Biology (hemostatic material), Qingpu Technology (small Mass spectrometry), Guoke Junhao (POCT), Angkai Life (methylation detection reagents), Alpha Bio (monoclonal antibody protein) and many other start-up high-quality enterprises.